Opinion

Video

Identifying RAI-Refractory Disease: A Key Aspect of DTC Management

Daniel Bowles, MD, leads a discussion on radioactive iodine (RAI) refractory disease, exploring the incidence and resistance levels, and provides recommendations for identifying patient populations who are ineligible for radioiodine treatment.

Related Videos
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video